NOT KNOWN DETAILS ABOUT HEMGENIX

Variety of eligible individuals: CDEC mentioned the uncertainty in the amount of people with reasonably severe to intense hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who are labeled as obtaining moderate or average illness can have a extreme bleeding phenotype,